4D Biomaterials
Andrew Naylor has a diverse work experience in the pharmaceutical industry. Andrew is currently serving as the Head of R&D Operations at 4D Biomaterials since September 2020. Prior to this, they worked at Upperton Limited as the R&D Director from August 2015 to September 2020. In this role, they led a team of R&D scientists, contributed to significant business expansion, managed successful collaborative projects, and played a key role in expanding the business into IMP manufacture. Before joining Upperton Limited, Andrew was the Head of Process Development at Critical Pharmaceuticals from May 2007 to July 2015. Andrew also worked as a Supercritical Fluid Scientist at Critical Pharmaceuticals from March 2006 to May 2007.
Andrew Naylor obtained their PhD in Polymer Chemistry from the University of Nottingham between 2003 and 2006.
This person is not in any teams
4D Biomaterials
4Degra® is a unique, patent-protected platform technology and is the ONLY route to 3D-printing high resolution biodegradable medical devices. The technology boosts excellent 3D-printing resolution, unique tunability in strength, elasticity and biodegrability as well as outstanding shape memory properties. Game-changing properties in themselves PLUSthe ability to 3D-print medical devices from nano to macro scale will lead to far superior patient experiences compared with the next best alternatives.